TITLE

COMMENTARY: Peginterferon &Alfa;-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections

AUTHOR(S)
Koretz, Ronald L.
PUB. DATE
January 2005
SOURCE
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that peginterferon &Alfa;-2a improved the hepatitis C virologic (HCV) response in concurrent HIV and chronic hepatitis C virus infections. Regardless of whether progression of liver disease is more rapid, the fact that HIV patients are living longer allows more time for development of end-stage disease. The absolute response rates in patients as a whole, and in the HCV genotype 1 subgroups, were higher in the industry-sponsored trial than in the National Institute of Health-sponsored trial.
ACCESSION #
15851776

 

Related Articles

  • Alcohol Metabolism Increases the Replication of Hepatitis C Virus and Attenuates the Antiviral Action of Interferon. McCartney, Erin M.; Semendric, Ljiljana; Helbig, Karla J.; Hinze, Susan; Jones, Brett; Weinman, Steven A.; Beard, Michael R. // Journal of Infectious Diseases;12/15/2008, Vol. 198 Issue 12, p1766 

    The interactions between hepatitis C virus (HCV) and alcohol metabolism are not well understood. To determine the effect that alcohol metabolism has on HCV replication and the antiviral action of interferon (IFN), Huh-7 cells that harbor HCV replication and metabolize ethanol via the introduced...

  • Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. Kobayashi, Masahiro; Ikeda, Kenji; Arase, Yasuji; Suzuki, Yoshiyuki; Suzuki, Fumitaka; Akuta, Norio; Hosaka, Tetsuya; Murashima, Naoya; Saitoh, Satoshi; Someya, Takashi; Tsubota, Akihito; Kumada, Hiromitsu // Journal of Gastroenterology;2008, Vol. 43 Issue 1, p63 

    Background. A phase II randomized controlled trial was conducted in patients with compensated liver cirrhosis to investigate the inhibitory effect of branchedchain amino acid (BCAA) granules for oral use (TK-98) on disease progression. Methods. Patients who had compensated liver cirrhosis due to...

  • Management of Chronic Hepatitis C in Patients Co-Infected with HIV. Romero, Miriam; Pérez-Olmeda, Mayte; García-Samaniego, Javier; Soriano, Vicente // Drug Safety;2004, Vol. 27 Issue 1, p7 

    Hepatitis C virus (HCV) infection is a significant public health problem and one of the most important causes of chronic liver disease worldwide. Co-infection with HCV and HIV occurs frequently, mainly because both viruses share the same transmission routes. In recent years, the life expectancy...

  • Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. Uka, Kiminori; Suzuki, Fumitaka; Akuta, Norio; Sezaki, Hitomi; Suzuki, Yoshiyuki; Hosaka, Tetsuya; Someya, Takashi; Kobayashi, Masahiro; Saitoh, Satoshi; Arase, Yasuji; Ikeda, Kenji; Kumada, Hiromitsu // Journal of Gastroenterology;May2006, Vol. 41 Issue 5, p470 

    Background. Suppression of the progression to cirrhosis and hepatocellular carcinoma is important, especially for young hepatitis C virus (HCV)-infected patients. The aim of this study was to analyze the response to interferon (IFN) monotherapy in young HCV patients. Methods. Between 1989 and...

  • A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis. Poynard, Thierry; Bedossa, Pierre; Chevallier, Michèle; Mathurin, Philippe; Lemonnier, Catherine; Trepo, Christian; Couzigou, Patrice; Payen, Jean Louis; Sajus, Marc; Costa, Jean Marc; Vidaud, Michel; Chaput, Jean Claude // New England Journal of Medicine;6/1/95, Vol. 332 Issue 22, p1457 

    Background: We studied the effects of long-term treatment with interferon on histologic features of the liver and serum alanine aminotransferase concentrations in patients with chronic non-A, non-B hepatitis. Methods: Consecutive patients who met the inclusion criteria were enrolled in the...

  • A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis. Poynard, Thierry; Bedossa, Pierre; Chevallier, Michèle; Mathurin, Philippe; Lemonnier, Catherine; Trepo, Christian; Couzigou, Patrice; Payen, Jean Louis; Sajus, Marc; Costa, Jean Marc; Vidaud, Michel; Chaput, Jean Claude // New England Journal of Medicine;6/1/95, Vol. 332 Issue 22, p1457 

    Background: We studied the effects of long-term treatment with interferon on histologic features of the liver and serum alanine aminotransferase concentrations in patients with chronic non-A, non-B hepatitis. Methods: Consecutive patients who met the inclusion criteria were enrolled in the...

  • Early and Sustained Virological Response in Non-Responders with Chronic Hepatitis C: A Randomized Open-Label Study of Pegylated Interferon-α-2a versus Pegylated Interferon-α-2b. Scotto, Gaetano; Faziov, Vincenzina; Fornabaio, Chiara; Tartaglia, Alessandra; Di Tullio, Rocco; Saracino, Annalisa; Angarano, Gioacchino // Drugs;2008, Vol. 68 Issue 6, p791 

    OBJECTIVES: The purpose of this randomized open-label study was to assess the efficacy of treatment with pegylated interferon-α-2a versus pegylated interferon-α-2b, both plus ribavirin, in inducing early and sustained virological response (EVR and SVR) in chronic hepatitis C...

  • Randomized Controlled Trial of Lymphoblastoid Interferon α for Chronic Hepatitis C (Comparison of 9-MU and 6-MU Doses). Yoshioka, Kentaro; Yano, Motoyoshi; Kusakabe, Atsuhiko; Hirofuji, Hideo; Fuji, Akihiko; Kuriki, Junsuke; Arao, Motohiro; Murase, Kenichi; Kidokoro, Ryuichi; Kakumu, Shinichi // American Journal of Gastroenterology;Jan1999, Vol. 94 Issue 1, p164 

    Objective: We conducted a randomized controlled trial to compare the efficacy of two different dosages of lymphoblastoid interferon α (IFN) for the treatment of chronic hepatitis C. Methods: Eighty-four patients with chronic hepatitis C were enrolled and randomly assigned into the two groups;...

  • The "Hit Hard And Hit Earl" Strategy To Treat Chronic Hepatitis C. Barreiros, Ana Paula; Schlaak, Jörg; Gerken, Guido; Galle, PR; Löhr, Hanns // Internet Journal of Gastroenterology;2003, Vol. 2 Issue 2, p22 

    Daily dosed interferon-alpha may prevent mutations of the hepatitis C virus (HCV) quasi-species and may therefore be more efficient in the treatment of chronic hepatitis C than the conventional therapy regimen given three times a week. The drop of viral load in the initial therapy phase has been...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics